Skip to main content
KBS_Icon_questionmark link-ico

Research & Impact

 

Our research

We have a multidisciplinary research portfolio that spans the entire cancer patient journey in the Comprehensive Cancer Centre and focuses on a Molecule to Medicine strategy in the Institute of Pharmaceutical Sciences (IPS).

In the Comprehensive Cancer Centre research focuses on fundamental science discovery to improve patient response, and we have a forward and reverse translational vision. Areas of research cover cancer genomics, haemato-oncology, breast cancer biology, epidemiology, cancer cell biology, cancer imaging, the tumour microenvironment and immunotherapy. Research teams are developing alternative and individualised patient care options, including developing and running clinical trials.

The IPS has major research programmes in anticancer chemotherapy, novel therapies for infectious diseases and antimicrobial resistance, drug discovery/technologies for treating respiratory diseases. Research teams have developed a novel prognostic biomarker for prostate cancer and are conducting commercial and clinical development of a number of classes of new drug molecules for Parkinson’s disease, infection and inflammatory lung disease. Clinical researchers have established new clinical services and prescribing guidelines for drug use in anticoagulation, antibiotic use in children and the use of psychotrophic medicines.

student working in lab

 

 

Our impact

 

 

flagship centres

Breast Cancer Now

Breast Cancer Now

Breast Cancer Now is the UK's largest breast cancer research charity and is dedicated to funding…